Caseware UK (AP4) 2024.0.164 2024.0.164 2025-01-312025-01-312025-05-27Consultancyfalse0true2024-02-010true 14087371 2024-02-01 2025-01-31 14087371 2023-06-01 2024-01-31 14087371 2025-01-31 14087371 2024-01-31 14087371 c:Director1 2024-02-01 2025-01-31 14087371 d:CurrentFinancialInstruments 2025-01-31 14087371 d:CurrentFinancialInstruments 2024-01-31 14087371 d:CurrentFinancialInstruments d:WithinOneYear 2025-01-31 14087371 d:CurrentFinancialInstruments d:WithinOneYear 2024-01-31 14087371 d:ShareCapital 2025-01-31 14087371 d:ShareCapital 2024-01-31 14087371 d:RetainedEarningsAccumulatedLosses 2025-01-31 14087371 d:RetainedEarningsAccumulatedLosses 2024-01-31 14087371 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2025-01-31 14087371 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2024-01-31 14087371 c:EntityHasNeverTraded 2024-02-01 2025-01-31 14087371 c:FRS102 2024-02-01 2025-01-31 14087371 c:AuditExempt-NoAccountantsReport 2024-02-01 2025-01-31 14087371 c:FullAccounts 2024-02-01 2025-01-31 14087371 c:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 14087371 2 2024-02-01 2025-01-31 14087371 e:PoundSterling 2024-02-01 2025-01-31 iso4217:GBP xbrli:pure

Registered number: 14087371









MEDISECO LIMITED







UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2025

 
MEDISECO LIMITED
REGISTERED NUMBER: 14087371

BALANCE SHEET
AS AT 31 JANUARY 2025

2025
2024
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
122
1,873

Cash at bank and in hand
 5 
1
5,980

  
123
7,853

Creditors: amounts falling due within one year
 6 
(138)
(7,753)

Net current (liabilities)/assets
  
 
 
(15)
 
 
100

Total assets less current liabilities
  
(15)
100

  

Net (liabilities)/assets
  
(15)
100


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
(115)
-

  
(15)
100

Page 1

 
MEDISECO LIMITED
REGISTERED NUMBER: 14087371
    
BALANCE SHEET (CONTINUED)
AS AT 31 JANUARY 2025

For the year ended 31 January 2025 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 27 May 2025.




................................................
J O Thomas
Director

The notes on pages 3 to 5 form part of these financial statements.
Page 2

 
MEDISECO LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

1.


General information

Mediseco Limited is a private company, incorporated in England and Wales, limited by its share capital.    the company is dormant and did not trade during the year.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.4

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 3

 
MEDISECO LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

2.Accounting policies (continued)

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.

 
2.8

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The Company has no employees other than the directors, who did not receive any remuneration (2024 - £NIL).


4.


Debtors

2025
2024
£
£


Amounts owed by joint ventures and associated undertakings
93
1,873

Other debtors
29
-

122
1,873


Page 4

 
MEDISECO LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

5.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
1
5,980

1
5,980



6.


Creditors: Amounts falling due within one year

2025
2024
£
£

Corporation tax
-
6,679

Accruals and deferred income
138
1,074

138
7,753



7.


Financial instruments

2025
2024
£
£

Financial assets


Financial assets measured at fair value through profit or loss
1
5,980




Financial assets measured at fair value through profit or loss comprise cash at bank and in hand.


8.


Controlling party

The Company is controlled by the director, J O Thomas, by virtue of his shareholding in J O Thomas Limited, as described in the Director's report.
 
Page 5